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responsible for that antiviral activity. Differential expres-
sion screens flagged a handful of candidates that were
selectively expressed in nonpermissive cell lines, and
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of these a single cDNA, first named CEM15, was foundand Molecular Biophysics
to specifically inhibit the replication of Vif-minus virusColumbia University College of Physicians
(Sheehy et al., 2002). The cDNA was similar to a familyand Surgeons
of genes that includes APOBEC1, encoding a cytidine701 West 168th Street
deaminase involved in mRNA editing (Teng et al., 1993),New York, New York 10032
and AID (for activation-induced cytidine deaminase;
Muramatsu et al., 1999), required for immunoglobulin
gene diversification (Muramatsu et al., 2000; Revy et al.,
2000). The implication of the data was that this particularA human gene with potent antiretroviral activity has
APOBEC family member, now known as APOBEC3G,recently been found to encode a new member of the
had antiviral activity, and that Vif had been acquired byfamily of cytidine deaminases, previously known to be
HIV-1 to somehow overcome that activity.involved in mRNA editing, immunoglobulin gene class
APOBEC3G has now proved to target HIV-1 throughswitching, and immunoglobulin gene hypermutation.
a remarkable mode of action (Figure 1). The enzyme isThe enzyme attacks viral DNA as it is synthesized in
incorporated at substantial levels into the virion particlesinfected cells and prevents the formation of functional
of Vif-minus mutants; and upon their infection of naiveproviruses. The Vif gene of HIV-1 blocks this host re-
cells, this encapsidated enzyme becomes activated tostriction and so allows virus replication.
deaminate many cytosine residues in the first (minus
polarity) strand of DNA as it is synthesized by reverseA seemingly minor (“auxiliary” or “accessory”) protein
transcriptase, converting these cytosines to uracils.encoded by HIV-1, the Vif protein, has been transformed
Analysis of the DNAs made by virions under conditionsinto an exceedingly hot topic with the recent identifica-
that promote reverse transcription in vitro (so-calledtion and characterization of its target, as reported by
endogenous reactions) show similar deamination. Whilemultiple laboratories both at the Cold Spring Harbor
the original founding member of the gene family,Retrovirus Meeting and in a flurry of recent publications
APOBEC1, acts on RNA and deaminates only a single(Harris et al., 2003; Lecossier et al., 2003; Mangeat et
cytosine residue in its target apolipoprotein B mRNA toal., 2003; Mariani et al., 2003; Zhang et al., 2003). Vif’s
regulate its expression (Teng et al., 1993), APOBEC3Gmain function is now identified as blocking the action
is instead active on single-stranded DNA and is muchof an antiviral protein, APOBEC3G, a cytidine deaminase
more potent. As a result of its activity, about 1%–2% ofthat attacks the viral DNA as it is synthesized in the
all the cytosine residues in the viral DNA are converted toinfected cell. Much like the classical bacterial restriction
uracil. The mutations are observed both in preintegrativeenzymes (which were so named because they restrict
DNA and in postintegrated proviral DNAs. There is mod-
the unmodified DNA of incoming bacteriophages),
erate sequence specificity, with a preference for the
APOBEC3G acts to restrict HIV-1 by degrading its ge-
third dC residue in a Py-C-C sequence. However, there
nome before it can establish a successful infection. is no hint that the activity is significantly restricted to
APOBEC3G and Vif are thus newly appreciated warriors any more specific HIV-1 sequence; APOBEC3G blocks
in the long-standing battle between virus and host. highly divergent variants of HIV-1 and SIV, and also
The vif gene was originally identified as a small ORF acts on the distantly related EIAV and MuLV genomes
encoded by a multiply spliced mRNA of HIV-1, and vari- (Mangeat et al., 2003). The purified protein exhibits the
ously named orfA, sor, and finally vif for virus infectivity appropriate enzyme activity on single-stranded DNA in
factor. It has been known for many years that the viral vitro (Harris et al., 2003), and furthermore its activity
Vif protein significantly enhances HIV-1 replication in requires the amino acid residues expected to be impor-
certain cell types and lines (termed nonpermissive; ex- tant for function (those predicted in its relatives to lie in
amples include the H9, and CEM lines and PBMCs), a zinc binding motif and at the catalytic site; Mangeat
though it has no activity in other cell lines (termed per- et al., 2003; Zhang et al., 2003).
missive; examples include the 293, HeLa, SupT1, and After the attack by APOBEC3G, the heavily modified
CEM-SS lines). Its function requires that it be expressed viral DNA then apparently suffers either one of two fates.
in the cell that is responsible for the assembly and re- Some of the DNA is probably recognized by the host
lease of virion particles. A major advance in the field uracil-DNA glycosidases, which remove dU residues in
was made some years ago with the discovery that the DNA; the resulting abasic sites would in turn be recog-
nonpermissive phenotype was dominant over permis- nized by DNA base excision repair enzymes and thus
sive (in heterokaryons), suggesting that nonpermissive lead to cleavage and degradation of the DNA. Indeed,
cells expressed an antiviral activity that was inhibited viral DNA levels after infection by Vif-minus virions are
by Vif (Madani and Kabat, 1998; Simon et al., 1998a). low (Mangeat et al., 2003), and examination of the life-
This finding provoked a search for the cellular gene time of the viral DNA formed in nonpermissive settings
suggests a rapid loss after its synthesis (Fouchier et
al., 1996; Mariani et al., 2003). The viral cDNA is likely*Correspondence: goff@cancercenter.columbia.edu
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ently the important member for inhibition of HIV-1, other
members may have activity against other viruses. The
specificity of APOBEC3G for single-stranded DNA
would seem to be ideal for antiretroviral activity, since
it would target the critical time of reverse transcription
with minimal consequences on host DNA. Similar activ-
ity might well be effective on hepadnaviruses, which
enter cells with substantial regions of the genome in
the form of single-stranded DNA. The degradation of
incoming DNA, either single- or double-stranded, might
be an effective strategy against DNA viruses if the activ-
ity could be limited to the viral genomes. Such restricted
and targeted specificities would not be surprising for
the APOBECs; indeed, the most famous member of the
family, the AID enzyme, which specifically induces muta-
tions in the immunoglobulin genes (Muramatsu et al.,
Figure 1. Effects of APOBEC3G on HIV-1 Replication 2000; Revy et al., 2000), is probably targeted to single-
(A) Vif-minus virus assembled in nonpermissive (APOBEC3G-posi- stranded DNA present during their transcription (Pham
tive) cells. The virus encapsidates APOBEC3G and suffers massive et al., 2003) (though if expressed out of context, AID
hypermutation of the minus-strand DNA made by reverse tran-
[Petersen-Mahrt et al., 2002] and other APOBECs [Harrisscriptase upon infection.
et al., 2002] can act on other DNAs and increase the(B) Vif-positive virus assembles with exclusion of APOBEC3G from
rate of mutation more generally). Similarly, deaminationthe virion, and its genome remains intact upon infection.
of incoming viral RNAs by enzymes with appropriate
specificity for RNA sequences or structures could also
be imagined.uniquely sensitive to this mechanism of attack, because
Recent work examining the APOBEC enzymes ofthe transient DNA intermediates of reverse transcription
other species shows that the human enzyme may beare single-stranded after RNase H action on the prod-
specifically bound by HIV-1 Vif and so uniquely sensitiveucts and cannot be repaired like double-stranded DNA,
to inactivation by Vif (Mariani et al., 2003). In particular,using its complementary DNA strand. The presence of
the mouse genome encodes a very similar enzyme,many dU residues in the minus strand DNA may specifi-
though there are not as many members in the murinecally impact on the course of reverse transcription (Klar-
family (the nomenclature is not established; perhaps themann et al., 2003), but the magnitude of these effects
closest murine enzyme will be APOBEC3), and primatesis not certain. Alternatively, if reverse transcription is
such as the African green monkey contain a close mem-successfully completed at low efficiency and the re-
ber. These enzymes also turn out to be efficiently tar-sulting double-stranded DNA is integrated into the host
geted for incorporation into HIV-1 virions assembled in
genome, the massive C-to-U conversion on the minus
these hosts, are antiviral proteins active against HIV-1,
strand leads to correspondingly massive G-to-A hyper-
and induce the same level of hypermutation. Remark-
mutation of the plus strand. The resulting provirus is so
ably, the murine, Chinese hamster, and most primate
heavily mutated that it cannot encode functional viral versions are relatively resistant to the effects of HIV-1
proteins. The DNA sequences documenting this massive Vif and so inhibit even wild-type HIV-1 replication. (The
hypermutation of vif-minus HIV-1 proviruses are probably chimpanzee version, like the human, is sensitive to Vif.)
the most dramatic demonstration of APOBEC3G activity Presumably these enzymes serve as true restriction fac-
(Harris et al., 2003; Lecossier et al., 2003; Mangeat et tors that prevent or limit HIV-1 replication in their respec-
al., 2003; Mariani et al., 2003; Zhang et al., 2003). tive hosts. These results suggest that Vif may have
The mechanism of action by which Vif blocks evolved specifically to inhibit human APOBEC3G and so
APOBEC3G is not yet completely clear. Vif apparently to allow HIV-1 to replicate well in humans, and perhaps a
binds to APOBEC3G (Mariani et al., 2003), but it is uncer- few very closely related species.
tain if Vif binds stably or transiently, or whether such The APOBEC enzymes are incorporated into the virion
binding is required for Vif function. Vif significantly re- particles of other retroviruses besides HIV-1, including
duces the level of APOBEC3G protein encapsidated into even the simple murine leukemia viruses (MuLVs; (Harris
virions. It could do this by mediating its degradation in et al., 2003; Mangeat et al., 2003; Mariani et al., 2003).
the virus-producing cell, since at least a modest reduc- These viruses do not encode Vif or any known Vif-like
tion in intracellular levels is observed in Vif-expressing activity, and yet the enzymes do not seem to have pro-
lines. Alternatively, Vif may somehow specifically ex- foundly inhibitory effects on these viruses. How these
clude APOBEC3G from the nascent virion without de- viruses escape the antiviral activity of the APOBECs is
grading it, perhaps by blocking a binding site needed unknown. It may be that they replicate as best they can
for its incorporation. Vif is itself probably also incorpo- even in the face of this inhibitory activity; indeed, the
rated into virions (though this is controversial), and in HIV-1 Vif protein has at least sometimes been observed
this case would also be present at the time of infection. to enhance MuLV infectivity (Simon et al., 1998b), sug-
It thus remains possible that Vif also directly inhibits gesting that APOBECs may have some weak basal anti-
APOBEC3G enzyme activity. viral activity that the MuLVs endure, but are happy to
The human APOBECs constitute a large gene family see eliminated.
Many questions are raised by these findings. How(at least ten members), and though APOBEC3G is appar-
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Mahrt, S.K., Watt, I.N., Neuberger, M.S., and Malim, M.H. (2003).is APOBEC3G targeted to assembling virions: through an
Cell 113, 803–809.interaction with the viral genome or with some viral protein?
Harris, R.S., Petersen-Mahrt, S.K., and Neuberger, M.S. (2002). Mol.How exactly does Vif mediate lowering of APOBEC3G lev-
Cell 10, 1247–1253.els in the infected cell, and how does it exclude it from
Hatziioannou, T., Cowan, S., Goff, S.P., Bieniasz, P.D., and Towers,virions? Why does Vif not act on the APOBECs of nonhu-
G.J. (2003). EMBO J. 22, 385–394.
man species? How do retroviruses without Vif manage
Klarmann, G.J., Chen, X., North, T.W., and Preston, B.D. (2003). J.to replicate in the face of this antiviral enzyme? Do they
Biol. Chem. 278, 7902–7909.
encode or recruit an unidentified Vif-like activity, or do
Lecossier, D., Bouchonnet, F., Clavel, F., and Hance, A.J. (2003).
they employ some other completely novel means of pro- Science 300, 1112.
tecting their DNA? What other members of the APOBEC Madani, N., and Kabat, D. (1998). J. Virol. 72, 10251–10255.
family have antiviral activity, what viruses do they act
Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono,
on, and what are the DNA or RNA forms of the viral D. (2003). Nature 424, 99–103.
genomes on which they act? Are there other DNA modi- Mariani, R., Chen, D., Schrofelbauer, B., Navarro, F., Koenig, R.,
fying enzymes with other enzymatic activities that attack Bollman, B., Muenk, C., Nymark-McMahon, H., and Landau, N.R.
incoming viral genomes and so act to restrict virus repli- (2003). Cell 114, 21–31.
cation? We can expect the answers to many of these Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai,
Y., and Honjo, T. (2000). Cell 102, 553–563.questions to be forthcoming rapidly.
Will these new findings translate to new antiviral treat- Muramatsu, M., Sankaranand, V.S., Anant, S., Sugai, M., Kinoshita,
K., Davidson, N.O., and Honjo, T. (1999). J. Biol. Chem. 274, 18470–ment for patients? Perhaps, but probably not right away.
18476.Overexpressing APOBEC3G by delivering the gene to
Petersen-Mahrt, S.K., Harris, R.S., and Neuberger, M.S. (2002). Na-target cells might override Vif’s ability to inactivate it
ture 418, 99–103.(Mariani et al., 2003), but there could be toxic conse-
Pham, P., Bransteitter, R., Petruska, J., and Goodman, M.F. (2003).quences, and gene therapy today is not routinely practi-
Nature 424, 103–107.
cal. If the regulation of APOBEC3G gene expression is
Revy, P., Muto, T., Levy, Y., Geissmann, F., Plebani, A., Sanal, O.,studied, ways to induce the endogenous gene to higher
Catalan, N., Forveille, M., Dufourcq-Labelouse, R., Gennery, A., et
levels and in more cell types might be found. Probably al. (2000). Cell 102, 565–575.
the best hope is that the discovery of APOBEC3G will Sheehy, A.M., Gaddis, N.C., Choi, J.D., and Malim, M.H. (2002).
allow high-throughput screens for small molecules that Nature 418, 646–650.
inhibit Vif’s action. Drugs developed from such com- Simon, J.H., Gaddis, N.C., Fouchier, R.A., and Malim, M.H. (1998a).
pounds would induce a phenocopy of Vif-minus mutant Nat. Med. 4, 1397–1400.
viruses, and so would free the endogenous APOBEC3G Simon, J.H., Miller, D.L., Fouchier, R.A., Soares, M.A., Peden, K.W.,
and Malim, M.H. (1998b).EMBO J. 17, 1259–1267.to destroy the viral DNA and block virus spread.
The discovery of APOBEC3G identifies a new soldier Teng, B., Burant, C.F., and Davidson, N.O. (1993). Science 260,
1816–1819.in the continuous battle between host and virus. The
Zhang, H., Yang, B., Pomerantz, R.J., Zhang, C., Arunachalam, S.C.,enzyme can be added to a list of other dominant-acting
and Gao, L. (2003). Nature 424, 94–98.antiviral host defense mechanisms, collectively consid-
ered as part of the innate immune system acting in
parallel with the conventional adaptive immune system.
Many of the classical antiviral factors are induced by
interferon, including a double-stranded RNA-dependent
protein kinase (PKR), which shuts down translation in
infected cells; the Mx proteins, which block influenza
virus gene expression through unknown means; and the
oligo(A) synthetases, which activate a specific nuclease
(RNase L) to degrade both mRNAs and ribosomal RNAs.
Other newer factors may be constitutively expressed,
including the antiretroviral factors Fv1, Ref1, and Lv1,
which target the capsid protein of incoming retroviral
cores and prevent either reverse transcription or nuclear
entry of the viral DNA (Hatziioannou et al., 2003); and
ZAP, a factor which inhibits the accumulation of many
retroviral and alphaviral RNAs to prevent viral replication
(Gao et al., 2002). Odds are excellent that more novel
intracellular defenses against viral attack are yet to be
identified. Odds are also good that this ancient biologi-
cal warfare, like others, is not likely to end soon.
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